PocketAngel

An expert in your pocket.

The deck tells the story. The right question tests the story.

See a real report→Get started

Photo: Vitaly Gariev on Unsplash

The cost of one missed question

What 20 minutes would have caught.

The deal you almost passed on.

Three sharp questions

Be the investor founders WANT
on their cap table.

Sharp enough that founders take the next call.

Tap each card to see why it lands

Saves you a bad check. Wins you the next deal.

Same deck. Different reads.

Months of expert analysis, in minutes.

The team you don't have on staff.

On vibes
2 hours

$0 upfront

You read. You hope. You find out at month 18.

Consultant
3 months

$15-30K

Heavy report. Long cycle. The round closes before the report lands.

PocketAngel
20 minutes

Pay per deck

Three sharp questions. The risk the deck didn't lead with. A defensible verdict.

Live demo · real outputs

What 20 minutes looks like.

Upload, analyze, deliver.

pocketangel.co/dashboard
PDF
deck.pdf

Upload your deck

Engine analyzing…

Reading slides · cross-checking sources · drafting questions

OnePager
Indian Life-Sciences Series B
WATCH
3 questions to ask
→ On margins: price controls on 4 of 6 drugs not in the model
→ On supply: China-sourced API, no diversification disclosed
→ On continuity: single manufacturing site, no backup plan
Risk flags
RegulatorySupply chainGeopolitical
You make the call. We sharpen the questions.
What a 12-minute engine run looks like.
Pharmaceutical · Series A/B · India · grounding 0.909
The deck said

“Seven-molecule cardiometabolic drug portfolio. Anchor: a marine-lipid molecule for hypertriglyceridemia.”

What we found
→ India sources 60-70% of bulk drug requirements from China; supplier requalification requires 6-18 months — a critical production-risk window for the marine-lipid lead.
Industry data; API manufacturing dependencies
→ Four of six portfolio molecules fall within or adjacent to DPCO / NLEM price-controlled categories; expansion into other diabetes molecules would compress margins.
DPCO 2013; National List of Essential Medicines
→ No manufacturing location, capacity, or GMP certification disclosed; CMO-dependent models carry higher COGS.
Engine flag: missing disclosure
Verdict

WATCH, Lean INVEST contingent on audited financials, GMP-confirmed manufacturing, and API supply agreement disclosure for the lead molecule. You make the call.

Real outputs across sectors. Company names removed, findings verbatim.

Per deck. No subscription.

Try the first one for $10.

If we miss the question that mattered, we refund.

First OnePager
$10

Your first deck. One-time intro.

OnePager
$29

Per deck, every deck after.

Full Memo
$59

Brief + full memorandum.

Start with one deck — $10→

See pricing details →

How we work

Not advice. Better questions.

Advice tells you what to do. Better questions teach you what to ask.

We surface the questions. You apply the judgment.

No subscription.

Pay per deck. Skip when you don't need it.

No data shared.

Your decks are yours. Always.

No commitment.

You owe us nothing after the report lands.

Try it on your next deck.

$10 for your first OnePager. Refund if we miss the question that mattered.

Get started→